Loading
Life sciences · Journal article
Cirugía Española · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
En mujeres mayores con cáncer de mama precoz y receptores hormonales positivos, el valor de la biopsia del ganglio centinela (BGC) ha sido cuestionado por su escaso impacto pronóstico y terapéutico. Evaluar la utilidad de la BGC en esta población. Efectuamos una revisión sistemática conforme a la guía PRISMA 2020. Se buscaron estudios publicados entre 2014-2024 en PubMed, Cochrane Library y Google Académico, que analizaban la implicación de la BGC en mujeres ≥ 60 años con tumores cT1-T2N0, RH+, HER2−, sometidas a cirugía primaria, y elaboramos un metaanálisis por subgrupos centrado en dominios homogéneos. De los 8.396 estudios identificados, 35 cumplieron los criterios de inclusión. La omisión de la BGC no afectó a la supervivencia ni aumentó las recurrencias, reduciendo la indicación de terapias adyuvantes. En mujeres mayores con cáncer de mama precoz de bajo riesgo, la omisión de la BGC es segura y no compromete la supervivencia. In older women with early-stage, hormone receptor-positive breast cancer, the value of sentinel lymph node biopsy (SLNB) has been questioned due to its limited prognostic and therapeutic impact. To evaluate the usefulness of SLNB in this population. A systematic review was conducted in accordance with the PRISMA 2020 guidelines. Studies published between 2014 and 2024 were searched in PubMed, Cochrane Library, and Google Scholar, analyzing the impact of SLNB in women ≥ 60 years of age with cT1-T2N0, RH+, HER2− tumors undergoing primary surgery, and we performed a meta-analysis by subgroups focused on homogeneous domains. Of the 8,396 studies identified, 35 met the inclusion criteria. Omitting SLNB did not affect survival or increase recurrences, reducing the indication for adjuvant therapies. In older women with low-risk early breast cancer, omitting SLNB is safe and does not compromise survival.